Lenacapavir and Cabotegravir Significantly Reduce HIV Infection Rates

The shift from daily pills to long-acting injectables is fundamentally changing the math of HIV prevention. For years, the primary barrier to PrEP (pre-exposure prophylaxis) success has been adherence; if a patient misses doses, the protection vanishes. But the emergence of lenacapavir and cabotegravir is removing that human error from the equation.

Lenacapavir’s Impact in PURPOSE 1 and PURPOSE 2 Trials

The data from Gilead’s PURPOSE program suggests a near-total disruption of HIV transmission in high-risk groups. In the PURPOSE 1 study, which focused on women at risk of HIV, twice-yearly lenacapavir demonstrated a 100% reduction in HIV incidence. This performance significantly outperformed both the background HIV incidence and the group using TDF/FTC.

The results remained strong across different demographics. The PURPOSE 2 study involved 3,273 cisgender men who have sex with men, transgender people, and non-binary individuals. In this cohort, 99.9% of participants in the lenacapavir group did not acquire HIV. Specifically, there were only two incident cases among 2,180 participants, resulting in an incidence of 0.10 per 100 person-years.

When compared to once-daily TDF/FTC, twice-yearly lenacapavir was 89% more effective. The disparity is stark: while the lenacapavir group saw minimal infections, the TDF/FTC group recorded nine incident cases among 1,087 individuals.

The Mechanics and Safety of Capsid Inhibition

However, timing remains critical.

Safety profiles across the trials have been generally favorable, though injection-site reactions are the most common side effect. In the PURPOSE 1 study, 68.8% of lenacapavir participants experienced these reactions, though they were typically mild and decreased over time. Serious adverse events were rare, occurring in 2.8% of lenacapavir participants compared to 4.0% in the TAF/FTC group.

Cabotegravir’s Resilience Against Treatment Interruptions

While lenacapavir dominates the new data, cabotegravir continues to prove its utility in real-world scenarios where medical care is inconsistent. Reporting from Medpagetoday on August 3, 2026, noted that cabotegravir PrEP remained effective among U.S. women even when treatment interruptions occurred.

The OPERA cohort data showed no cases of incident HIV over more than one year of follow-up. This suggests that the long-acting nature of the drug provides a critical safety net for populations that struggle with the rigid schedules of daily oral medication.

Economic Viability and Deployment in Africa

The transition to long-acting treatment is not just a medical hurdle but a financial one. Modeling analysis published in Nature suggests that a combination of lenacapavir and cabotegravir could substantially decrease HIV deaths and mother-to-child transmission in Eastern and Southern Africa (ECSWA).

The cost-effectiveness of this rollout depends heavily on the annual price per person.

Annual Cost per Person	Cost-Effectiveness Threshold
$140 ($80 drug / $60 delivery)	Effective if viral suppression on ART is below 93% (e.g., South Africa, Zimbabwe, Ethiopia)
$100	Likely cost-effective in almost all settings

The researchers suggest prioritizing this treatment for those who cannot adhere to daily oral drugs due to stigma, food insecurity, mental health challenges, or alcohol misuse. There is also a hypothesis that offering long-acting treatment could bring people who have completely stopped care back into the medical system.

Despite the promise, certain clinical constraints remain. Both cabotegravir and lenacapavir have drug interactions with rifampicin, which can lower the levels of the antiretrovirals in the body. Additionally, while cabotegravir is viewed as safe during pregnancy, data for lenacapavir is more limited, with one study involving 193 pregnancies identifying no safety issues to date.